The Null Result Problem: How Clinical Trials That Fail to Publish Are Quietly Corrupting the Scientific Record

Every year, research institutions across the United States enroll hundreds of thousands of patients into clinical trials. Those participants endure blood draws, experimental infusions, extended follow-up visits, and in some cases significant physical risk — all in service of generating knowledge that might eventually benefit others. It is a compact built on trust. What most participants do not know is that a meaningful portion of the data they help produce will never be seen by another scientist.

The phenomenon has a clinical name — publication bias — but that term fails to capture the full weight of what occurs. When trials with positive outcomes are published at rates far exceeding those with negative or inconclusive findings, the scientific literature stops functioning as a reliable map of what has been tried and what has been learned. It becomes, instead, a curated highlight reel. And researchers navigating by that reel are, by definition, navigating blind.

The Disappearing Data Problem

The scale of the problem is not trivial. A 2020 analysis published in PLOS ONE estimated that roughly half of all clinical trials registered with ClinicalTrials.gov — the federal database maintained by the National Library of Medicine — had failed to report results within 24 months of completion, despite a legal obligation under the 2007 FDA Amendments Act to do so within 12 months for most applicable studies. The gap between regulatory mandate and actual compliance has persisted across administrations, partly because enforcement has historically been inconsistent and penalties rarely applied.

The downstream effects compound quickly. When a Phase II trial of a gene therapy candidate produces inconclusive results and those results are never published, the next research team evaluating the same therapeutic target has no way of knowing that the path has already been walked — and found wanting. They apply for funding, recruit patients, run the experiment again, and arrive at the same inconclusive endpoint. The process is not merely redundant. It is actively harmful, consuming finite research dollars, delaying work on more promising targets, and exposing additional patients to interventional risk for no marginal scientific gain.

Institutional Incentives and the Publication Threshold

Understanding why negative results disappear requires understanding who controls the decision to publish and what they stand to gain or lose from doing so.

Academic researchers face promotion and tenure systems that reward publication in high-impact journals. Those journals, operating under competitive submission pressures and reader-engagement incentives of their own, have historically favored novel, affirmative findings over careful documentation of what did not work. A Phase III trial demonstrating statistically significant efficacy is a publishable event. A Phase II trial showing no discernible effect over placebo is, in the editorial calculus of most flagship journals, considerably less so.

Biotech and pharmaceutical sponsors face a different but equally powerful set of pressures. A negative trial result, once public, can move stock prices, complicate investor relations, and signal to competitors that a particular therapeutic avenue has been explored and closed. The incentive to file the data, satisfy internal compliance requirements, and move on without broadcasting the failure is rational from a business standpoint — and corrosive from a scientific one.

Academic medical centers, which frequently serve as trial sites and receive overhead payments tied to sponsored research, occupy an uncomfortable middle position. They benefit from industry partnerships and have limited institutional appetite for antagonizing sponsors by insisting on full data disclosure.

The Phantom Signal Effect

The most operationally dangerous consequence of systematic non-publication is what might be called the phantom signal: the false impression, created by a literature saturated with positive results, that a biological target or therapeutic mechanism is more validated than it actually is.

Consider a hypothetical scenario in the context of gene editing therapies — an area of intense contemporary investment. If five independent research groups test a novel delivery vector for CRISPR-based constructs and three find no meaningful uptake in the target tissue, but only the two groups with encouraging data publish, the literature presents a 100 percent success rate. The next group to enter the field, reading that literature and designing their program accordingly, proceeds under a fundamentally false premise. Their trial is built on a foundation of incomplete information masquerading as consensus.

This is not a hypothetical confined to gene therapy. It has been documented across oncology, cardiology, psychiatry, and infectious disease. The phantom signal problem is domain-agnostic. Wherever publication bias operates, it manufactures false confidence.

Structural Gaps in Regulatory Oversight

Federal law theoretically addresses this problem. The requirements established under the FDA Amendments Act of 2007, and further clarified through a 2016 rule issued by the Department of Health and Human Services, mandate that sponsors of applicable clinical trials submit results to ClinicalTrials.gov within specified timeframes. Civil monetary penalties of up to $10,000 per day are authorized for non-compliance.

In practice, enforcement has been limited. A 2015 investigation by STAT News found that the National Institutes of Health and the FDA had never formally fined a sponsor for failing to report results. Subsequent years brought incremental improvement in compliance rates, but the reporting gap remains substantial — particularly for industry-sponsored trials that fall outside the most closely scrutinized regulatory categories.

The NIH has made public commitments to prioritize results reporting as a condition of grant funding, and some academic institutions have implemented internal audit mechanisms. But commitment and enforcement are different things. Absent consistent regulatory consequence, the structural incentive to bury inconvenient findings remains largely intact.

Toward a More Complete Scientific Record

Several reform pathways have been proposed by researchers, ethicists, and policy advocates, and each merits serious institutional consideration.

Mandatory prospective registration with results-linked publication requirements would create a traceable chain from trial initiation to data disclosure. If a trial is registered, a results record — positive, negative, or inconclusive — should follow within a defined window, with genuine enforcement consequences for non-compliance. The infrastructure for this already exists; what is missing is the political and regulatory will to apply it consistently.

Journals occupy a parallel responsibility. Several publications, including PLOS Medicine and Trials, have adopted policies explicitly welcoming negative and null results. Broader adoption of these standards across the journal landscape, including among high-impact outlets where publication pressure is most acute, would begin to rebalance the editorial incentive structure.

Funding agencies, including the NIH and the major private foundations that support biomedical research in the United States, could condition continued funding on demonstrated compliance with reporting obligations. Researchers or institutions with documented histories of non-disclosure could be rendered ineligible for future awards — a consequence with sufficient weight to shift institutional behavior.

Finally, systematic review infrastructure needs to more aggressively account for the data that is absent, not merely the data that is present. Meta-analyses that fail to model for publication bias are, in effect, conducting their synthesis on a curated subset of the full evidence base. Funnel plot asymmetry analysis and other statistical tools for detecting suppressed findings should be standard practice, not methodological refinements deployed only by the most rigorous research teams.

The Obligation to the Full Record

Clinical research is, at its core, a public undertaking. Even when funded privately, it depends on patients who volunteer their time and their bodies, on regulatory frameworks built by public institutions, and on a scientific commons that only functions if its members contribute honestly to it.

When negative results disappear, that commons is diminished. Researchers chase phantom signals. Funding agencies allocate resources to replicated failures. Patients enroll in trials designed around incomplete information. And the promise that every trial result will eventually shape the trajectory of medicine — the promise that makes participation meaningful — goes quietly unkept.

The data exists. It sits in institutional servers and sponsor archives and the filing cabinets of academic departments that have long since moved on to the next funded project. Recovering it, publishing it, and building it into the living record of what science knows and does not know is not a peripheral concern. It is a precondition for the kind of evidence-based medicine that the field claims to practice.